Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Dovetail Genomics LLC is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units, suggesting that while the company's focus is within biotechnology, its applications touch upon several different technical sub-specialties. This distribution requires the company to navigate the specific standards of 3 distinct art units. The presence of 4 pending office actions indicates a moderate level of active engagement with the USPTO.
The prosecution workload is spread among 4 distinct examiners, with no single examiner handling more than one active matter. POHNERT, STEVEN C is identified as the busiest examiner, responsible for 1 busiest examiner pending office action. This means that each of the 4 pending office actions is being reviewed by a different individual, providing a diverse range of examiner feedback across the portfolio. This decentralized structure among 4 distinct examiners ensures that the portfolio's progress is not overly dependent on any single individual.
Practitioners must be prepared for four unique examination styles while maintaining consistency in their legal arguments. The fact that these are spread across 3 distinct art units adds another layer of complexity to the prosecution strategy. With 1 busiest examiner pending for POHNERT, STEVEN C, the workload is evenly distributed across the examining staff. This structure allows the company to advance multiple patent goals within the Biotechnology & Pharmaceuticals sector while benefiting from the feedback of several different technical groups and examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
| GIAMMONA, FRANCESCA FILIPPA | 1 | 37.3% | +58.8% |
| RAYMONDA, MATTHEW HAROLD | 1 | 40.0% | +47.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18780961 | METHODS FOR HUMAN LEUKOCYTE ANTIGEN TYPING AND PHASING | POHNERT, STEVEN C | — |
| 18768466 | Recovering Long-Range Linkage Information From Preserved Samples | GRAY, JESSICA | — |
| 18665851 | DENDRIMERS FOR GENOMIC ANALYSIS METHODS AND COMPOSITIONS | GIAMMONA, FRANCESCA FILIPPA | — |
| 18270027 | METHODS AND COMPOSITIONS FOR SEQUENCING LIBRARY PREPARATION | RAYMONDA, MATTHEW HAROLD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18780961 | METHODS FOR HUMAN LEUKOCYTE ANTIGEN TYPING AND PHASING | POHNERT, STEVEN C | — |
| 18665851 | DENDRIMERS FOR GENOMIC ANALYSIS METHODS AND COMPOSITIONS | GIAMMONA, FRANCESCA FILIPPA | — |
| 18270027 | METHODS AND COMPOSITIONS FOR SEQUENCING LIBRARY PREPARATION | RAYMONDA, MATTHEW HAROLD | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| 1682 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18780961 | METHODS FOR HUMAN LEUKOCYTE ANTIGEN TYPING AND PHASING | POHNERT, STEVEN C | 1683 | §101§103 | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18768466 | Recovering Long-Range Linkage Information From Preserved Samples | GRAY, JESSICA | 1682 | §103§112DP | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18665851 | DENDRIMERS FOR GENOMIC ANALYSIS METHODS AND COMPOSITIONS | GIAMMONA, FRANCESCA FILIPPA | — | §103§112Other | Non-Final OA | — | Pending | May 16, 2024 |
| 18270027 | METHODS AND COMPOSITIONS FOR SEQUENCING LIBRARY PREPARATION | RAYMONDA, MATTHEW HAROLD | 1684 | §102§103§112 | Non-Final OA | — | Pending | Jun 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDovetail Genomics LLC has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Steven C Pohnert has the most, with 1 of Dovetail Genomics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
